Literature DB >> 11051624

Survey on antibiotic usage in the treatment of urinary tract infections.

K G Naber1.   

Abstract

Ninety-two clinical microbiologists, infectious disease clinicians and clinicians with an interest in the management of urinary tract infections (UTIs) participated in an interactive session concerning the management of acute uncomplicated lower UTI. The antibacterials considered most appropriate as first-line agents were trimethoprim, co-trimoxazole, pivmecillinam, nitrofurantoin and fluoroquinolones. The current level of usage of fluoroquinolones for lower UTIs was, however, considered inappropriate by most delegates from a 'societal perspective', in terms of spread of resistance and potential impact on the environment.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11051624

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  9 in total

Review 1.  Uncomplicated urinary tract infection in women. Current practice and the effect of antibiotic resistance on empiric treatment.

Authors:  Lindsay Nicolle; Peter A M Anderson; John Conly; Thomas C Mainprize; Jamie Meuser; J Curtis Nickel; Vyta M Senikas; George G Zhanel
Journal:  Can Fam Physician       Date:  2006-05       Impact factor: 3.275

2.  Fluoroquinolone-resistant urinary isolates of Escherichia coli from outpatients are frequently multidrug resistant: results from the North American Urinary Tract Infection Collaborative Alliance-Quinolone Resistance study.

Authors:  James A Karlowsky; Daryl J Hoban; Melanie R Decorby; Nancy M Laing; George G Zhanel
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

3.  Susceptibility of community Gram-negative urinary tract isolates to mecillinam and other oral agents.

Authors:  T Mazzulli; M Skulnick; G Small; W Marshall; D J Hoban; G G Zhanel; S Finn; D E Low
Journal:  Can J Infect Dis       Date:  2001-09

4.  Longitudinal surveillance of outpatient quinolone antimicrobial use in Canada.

Authors:  Shiona K Glass-Kaastra; Rita Finley; Jim Hutchinson; David M Patrick; Karl Weiss; John Conly
Journal:  Can J Infect Dis Med Microbiol       Date:  2014-03       Impact factor: 2.471

5.  Biological cost of single and multiple norfloxacin resistance mutations in Escherichia coli implicated in urinary tract infections.

Authors:  Patricia Komp Lindgren; Linda L Marcusson; Dorthe Sandvang; Niels Frimodt-Møller; Diarmaid Hughes
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

6.  Mutation rate and evolution of fluoroquinolone resistance in Escherichia coli isolates from patients with urinary tract infections.

Authors:  Patricia Komp Lindgren; Asa Karlsson; Diarmaid Hughes
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

7.  A single center observational study on emergency department clinician non-adherence to clinical practice guidelines for treatment of uncomplicated urinary tract infections.

Authors:  Catherine Zatorski; Mark Zocchi; Sara E Cosgrove; Cynthia Rand; Gillian Brooks; Larissa May
Journal:  BMC Infect Dis       Date:  2016-11-04       Impact factor: 3.090

8.  The efficacy of pivmecillinam: 3 days or 5 days t.i.d against community acquired uncomplicated lower urinary tract infections - a randomized, double-blinded, placebo-controlled clinical trial study protocol.

Authors:  Filip Jansåker; Niels Frimodt-Møller; Lars Bjerrum; Jenny Dahl Knudsen
Journal:  BMC Infect Dis       Date:  2016-12-01       Impact factor: 3.090

9.  Reversion of High-level Mecillinam Resistance to Susceptibility in Escherichia coli During Growth in Urine.

Authors:  Elisabeth Thulin; Måns Thulin; Dan I Andersson
Journal:  EBioMedicine       Date:  2017-08-24       Impact factor: 8.143

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.